Abstract
Doxorubicin is an antitumor antibiotic first isolated in 1969 from a fungi Streptomyces peucetius var caesius. Present study focuses on formulation and characterization of solid lipid nanoparticles of Doxorubicin. Fatty acid coacervation method was adopted to formulate solid lipid nanoparticles of Doxorubicin. Compritol 888 ATO and Precirol ATO 5 were explored as solid lipids with LIPOID S 75 being used as surfactant. Freeze dried solid lipid nanoparticles were compared with raw Doxorubicin in rat plasma using High Pressure Liquid Chromatography (HPLC) method using ultraviolet (UV) detector. Particle size measurements performed on Solid lipid nanoparticles of Doxorubicin revealed mean particle size of 200-300nm for optimized formulations and entrapment efficiency of close to 70%. Sucrose and Dextrose were suitable cryoprotectants to prepare freeze dried solid lipid nanoparticles. Doxorubicin loaded solid lipid nanoparticles exhibited sustained release pattern during in vitro release kinetics. In vivo pharmacokinetics study in Swiss albino rats revealed that encapsulation of Doxorubicin into solid lipid nanoparticles increased oral bioavailability of Doxorubicin by 3.6 folds when compared with raw Doxorubicin.
